A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
Completed · Phase 1
Conditions studied: Hepatic Impairment
In brief
The main purpose of this study is to evaluate the effect of varying degrees of impaired hepatic function (by Child-Pugh classification) on the pharmacokinetics (PK) of ABL001 after a single oral dose.
Key facts
- Study ID
- NCT02857868
- Run by
- Novartis Pharmaceuticals
- People needed
- 32
- Starts
- 2016-05-03
- Expected to finish
- 2017-07-20
- Last updated by the study team
- 2020-12-08
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- University of Miami / Clinical Research Services, Inc. — Miami, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- DaVita Clinical Research — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.